Indications

Pre-Clinical

IND-Enabling

Phase 1/2

Phase 3

GBM

PDAC

Angiosarcoma

Undisclosed Solid Tumors

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Baylor College of MedicinePhase 1, NCT04157127

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.
MD Anderson Cooper, UT Health Science Center<br /> Phase 1, NCT04552886

Glioblastoma

MD Anderson Cooper, UT Health Science Center
Phase 1, NCT04552886

Conducted in partnership with the MD Anderson Cooper Hospital, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established.
MD Anderson<br /> Phase 1, Pending

Sarcoma

MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.